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Abstract
Peritoneal carcinoma (PC) represents the second most frequent recurrence 
of primary colorectal cancer. The mainstay of treatment for patients with 
advanced stage colorectal cancer at risk of developing PC after initial 
intervention is surveillance. However, PC is not detectable by imaging, 
symptoms, or tumor markers with current techniques and technology. All 
though more research is needed, identifying the patient population at a 
high risk for developing PC and performing a mandatory second-look 
surgery (SLS), typically a laparotomy, with hyperthermic intraperitoneal 
chemotherapy (HIPEC) or prophylactic HIPEC at the time of initial 
intervention (cytoreductive surgery – CRS) seems to decrease mortality 
rates compared to the standard of care. 
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Introduction
Methods
A literature search was conducted through PubMed and Google 
Scholar in November 2018. A total of eleven article were selected 
based on the following exclusion criteria: 
1. Studies involving meta-analysis
2. Studies involving animals
3. Studies involving carcinomas other than advanced, 
primary colorectal carcinomas with the risk of PC
4. Studies involving adolescents. A final six articles were 
then analyzed and compared
Significant positive results were found in most of 
the articles, but outcome measures varied.
Strengths
➢ Allow for alternate treatment option for patients 
➢ Positive results to enforce further trials, including 
RCT (increased overall survival rates)
➢ Further narrowed the correct population that should 
be considered for SLS + HIPEC + CRS
Limitations
➢ Sample populations
➢ Study design 
➢ Outcome measures varied among studies 
➢ Adequate follow-up 
➢ Biases 
Future studies 
➢ Randomized trials 
➢ Identifying the population most at risk 
➢ Long-term outcomes of SLS + HIPEC +CRS
Discussion 
Comparison of Results 
Results 
The efficacy of second-look surgery with hyperthermic
intraperitoneal chemotherapy and cytoreductive surgery in 
adult patients with advanced stage colorectal carcinoma
In adult patients with advanced, primary colorectal 
cancer who are at a high risk of developing PC, 
second-look surgery with HIPEC and CRS 
should be considered over the standard of care 
to improve patient outcomes and reduce 
morality rates. Identifying the patient population 
at the highest risk for developing PC of colorectal 
origin is essential to achieve the greatest benefit of 
SLS with HIPEC and CRS. Second-look surgery is 
not without risks and the morbidity and mortality 
of the procedure should be further studied. Future 
studies should focus on identifying the patient 
population most at risk in addition to the long-
term outcomes of SLS with HIPEC + CRS. 
Conclusion
The evidence collected by each of the studies demonstrated a statistically significant 
reduction in the mortality rate in patients with advanced stage colorectal cancer at 
risk of developing PC. However, the evidence collected was not strong enough to 
confirm what patient population is at most risk of developing PC and who would 
benefit the most from mandatory second-look surgery. Three studies compared 
the use of second-look surgery after treatment of colorectal cancer. All three studies 
support the promising results of second-look surgery but acknowledged the need 
for conducting randomized trial to further support and validate the data. Two of 
the studies compared the effectiveness of cytoreductive surgery and intraperitoneal 
chemotherapy vs the standard of care (systemic chemotherapy and surveillance) to 
treat PC of colorectal origin. Both studies showed the overall benefit of 
cytoreductive surgery and intraperitoneal chemotherapy. However, only one 
showed statistically significant disease-free survival due to the early termination of 
the other study.  The final study recognized potential risk factors for developing 
PC to identify the correct population of patients that should be considered for 
second-look surgery with HIPEC and CRS.
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Boige V 
et al. 
(2011)
S N/A N/A S S S NS N/A S S
Brigand 
et al. 
(2015)
N/A S N/A S S NS S NS N/A S
Brouque
t et al. 
(2008)
S S N/A S S NS N/A S N/A N/A
Caravac
a G, et 
al. 
(2017)
S N/A S N/A S S S N/A S S
Cashin 
P. H. et 
al. 
(2015)
S S N/A S NS NS S S N/A N/A
Granath
F et al. 
(2012)
S N/A N/A N/A N/A NS N/A N/A S N/A
Key: S = Statistically Significant, NS = Not Significant, NA = Results Not Available  
Mandatory second look surgery + HIPEC in patients who have 
undergone CRS with the intent of cure and who are at high risk of 
developing PC, has allowed for early detection and treatment. Early and 
limited PC is undetectable with current diagnostics causing an increased 
mortality rate for patients with peritoneal metastasis of colorectal origin. 
Identifying individuals at high risk and implementing mandatory second-
look surgery can improve outcomes of those with advance colorectal 
cancer. This paper poses the following question: In adult patients with 
advanced, primary colorectal cancer who are at a high risk of 
developing PC, does SLS with HIPEC and CRS vs. the standard of 
care improve patient outcomes and reduce mortality rates.
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